What are the recommended therapeutic and maximum doses of olanzapine (oral and intramuscular) for adults?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Olanzapine Dosing for Adults

For oral olanzapine, the therapeutic dose range is 5-20 mg/day, with a maximum of 20 mg/day for schizophrenia and bipolar disorder; for intramuscular olanzapine, the recommended dose is 10 mg per injection, with a maximum of 30 mg total daily dose (given as 3 doses of 10 mg each, spaced at least 2-4 hours apart). 1

Oral Olanzapine Dosing

Standard Therapeutic Dosing

  • Starting dose: 5-10 mg/day
  • Target therapeutic range: 10-20 mg/day
  • Maximum approved dose: 20 mg/day 1

Special Populations

  • Elderly patients: Start with 2.5-5 mg/day; maximum 10 mg/day 2, 3
  • Debilitated patients or those predisposed to hypotension: Consider lower starting doses of 2.5-5 mg/day 1

Context-Specific Dosing

For chemotherapy-induced nausea/vomiting (CINV):

  • High-emetogenic chemotherapy: 10 mg orally once before chemotherapy, then daily for 3 days (total 4 days) 4, 5
  • Recent evidence suggests 2.5 mg/day may be equally effective with less sedation, particularly in elderly patients or those with breast cancer 6
  • Breakthrough nausea/vomiting: 5-10 mg orally daily 4

For acute agitation in schizophrenia/bipolar disorder:

  • Oral doses up to 40 mg/day have been studied in acute settings for the first 2 days, though this exceeds standard labeling 7

For Alzheimer's disease-related behavioral disturbances:

  • Starting dose: 2.5-5 mg/day at bedtime
  • Maximum: 10 mg/day 3

For delirium management:

  • Starting dose: 2.5-5 mg orally or subcutaneously
  • Usually given at bedtime; may repeat every 12-24 hours as needed 8

Intramuscular Olanzapine Dosing

Acute Agitation (Schizophrenia/Bipolar Mania)

  • Recommended dose: 10 mg IM 1
  • Alternative doses: 5 mg or 7.5 mg may be considered when clinical factors warrant 1
  • Repeat dosing: Additional doses up to 10 mg may be given, but:
    • Wait at least 2 hours after the first dose
    • Wait at least 4 hours after the second dose
    • Maximum total daily dose: 30 mg (three 10 mg injections) 1

Special Populations (IM)

  • Elderly patients: 5 mg/injection 1
  • Debilitated patients or those predisposed to hypotension: 2.5 mg/injection 1
  • Older patients with acute agitation: 2.5 mg IM, with increments of 2.5 mg to maximum 7.5 mg at no closer than 30-minute intervals 2

Critical Safety Considerations

Maximal Dosing Precautions

Assess for orthostatic hypotension before administering subsequent IM doses, especially with maximal dosing (3 doses of 10 mg each, 2-4 hours apart), as this is associated with substantial risk of significant orthostatic hypotension 1. Do not administer additional doses to patients with clinically significant postural changes in systolic blood pressure 1.

Drug Interactions (IM)

  • Do not combine with parenteral benzodiazepines for at least 2 hours after olanzapine IM administration due to risk of respiratory depression 2
  • Do not mix in syringe with diazepam (causes precipitation) or haloperidol (degrades olanzapine) 1
  • Lorazepam should not be used to reconstitute olanzapine for injection 1

Elderly-Specific Warnings

Olanzapine carries a boxed warning for increased mortality in elderly patients with dementia-related psychosis and should be used with extreme caution in this population 4, 1. When necessary, use the lowest effective doses (2.5-5 mg orally; 2.5 mg IM) 2, 3, 8.

Dose-Response Relationships

Research demonstrates that efficacy plateaus at doses above 10-15 mg/day, with minimal additional benefit at higher doses 9. The dose-response curve shows minimal rise in slope for doses exceeding 10 mg/day, and dopamine D2 receptor occupancy reaches the therapeutic threshold (65%) at approximately 12 mg/day 9.

Plasma concentration therapeutic range: 20-40 ng/mL (measured 12 hours post-dose) correlates with optimal D2-receptor occupancy (65-80%) and clinical response 10. However, only 35% of patients on doses of 2.5-20 mg/day achieve the suggested target range of 20-39 ng/mL, indicating significant inter-individual variability 11.

Practical Dosing Algorithm

  1. Start low: 5-10 mg/day orally (2.5-5 mg in elderly/debilitated)
  2. Titrate based on response: Increase to 10-15 mg/day if inadequate response after 1-2 weeks
  3. Consider plasma levels if: Non-response at 15 mg/day, suspected non-adherence, or potential drug interactions 9
  4. Doses >20 mg/day: Not routinely recommended; if considering, check plasma level first (target <60 ng/mL to minimize metabolic risks) 11
  5. For CINV: Use 10 mg/day (or 2.5 mg in elderly) for 4 days only; discontinue when symptoms resolve 6, 12

References

Guideline

nccn guidelines insights: antiemesis, version 2.2017.

Journal of the National Comprehensive Cancer Network : JNCCN, 2017

Guideline

antiemetics: asco guideline update.

Journal of Clinical Oncology, 2020

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.